DOCSLIB.ORG

7.2.2 Any Other Relevent Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

DR. VITHALRAO VIKHE PATIL FOUNDATION’S COLLEGE OF PHARMACY, VILAD GHAT, PO. MIDC, AHMEDNAGAR (MS) Phone No. (0241) 2778044 /2777217. Fax No. (0241) 2778044 E-mail ID : [email protected] Accredited by NAAC with Grade “B” (CGPA 2.72) Permanently Affiliated to Savitribai Phule Pune University, Pune. Approved by AICTE, PCI, New Delhi & Recognized by UGC, New Delhi ------------------------------------------------------------------------------------------------------------------------------------------------------ COMMUNITY OUT REACH ACTIVITY REPORTS (2019-2020) NAME OF NO. OF SR. NAME OF SPEAKER / DATE OF PLACE OF THE STUDENTS / NO. ACTIVITY ORGANISATION ACTIVITY ACTIVITY STAFF IF ANY PARTICIPATED B.S.D. UNIT OF DR.V.V.P.F’S, DONATION OF DR.V.V.P.F’S, COLLEGE OF FUND TO INDIAN 1. COLLEGE OF 30/07/2019 PHARMACY, 65 ASSOCIATION OF PHARMACY, VILAD VILAD GHAT, BLINDS [ IAB ] GHAT, A.NAGAR A.NAGAR HUMANITY DR.V.V.P.F’S, HELPING HANDS COLLEGE OF 2. TO KOLHAPUR & NSS UNIT 28/08/2019 PHARMACY, 50 SANGALI FLOOD VILAD GHAT, RELIEF FUND A.NAGAR 3. JAL SAKSHARATA ABHIYAAN & Ahmednagar Fort NSS UNIT 19/09/2019 50 PLASTIC MUKT Area BHARAT ABHIYAAN SWACHHATA ACTIVITY AT Ahmednagar Fort 4. NSS UNIT 19/09/2019 50 AHMEDNAGAR Area FORT DISTRIBUTION OF B.S.D. UNIT OF SNEHALAYA & GROCERRY , DR.V.V.P.F’S, MATOSHRI 5. SOAP,TOOTH COLLEGE OF 18/10/2019 10 VRUDHHASHRAM, PASTE, POWDER PHARMACY, VILAD AHMEDNAGAR etc. GHAT, A.NAGAR CANCER TUMOR CIVIL HOSPITAL MARKER TESTS , 6. ( MAHAHIND 10/01/2020 AKOLNER VILLAGE 25 THYROID LABS) & NSS UNIT ESTIMATION TEST C.B.C. ESTIMATION 7. & FREE EYE CIVIL HOSPITAL CHECKUP & 25 (MAHAHIND LABS) CATARACT AKOLNER VILLAGE & NSS UNIT 10/01/2020 OPERATIONS BETI BACHAO BETI Mr. Girish Kukreja 8. 10/01/2020 AKOLNER VILLAGE 25 PADHAO ABHIYAN & NSS UNIT AVAYAV DAAN & MR. S.M. AHIRE [ 9. NETRA DAAN 11/01/2020 AKOLNER VILLAGE 25 Civil Hospital ] ABHIYAN ENERGY AUDIT OF 10. NSS UNIT AKOLNER VILLAGE 25 VILLAGE 11/01/2020 TREE PLANTATION & OPEN LAND NSS UNIT 12/01/2020 AKOLNER VILLAGE 25 11. MAPPING COMPUTER 12. TEACHING TO ZP NSS UNIT 12/01/2020 AKOLNER VILLAGE 25 SCHOOL STUDENTS LECTURE ON SWAMI Mr. Raut , VIVEKANAND 13. Dr. R.K. Pardeshi 12/01/2020 AKOLNER VILLAGE 25 JAYANTI & & NSS UNIT PERSONALITY DEVELOPMENT LECTURE ON Army Retd. 14. “INDIAN LOC & Major NARAYAN 13/01/2020 AKOLNER VILLAGE 25 INDIAN ARMY “ RAUT GRAM 15. SWACHHATA NSS UNIT 13/01/2020 AKOLNER VILLAGE 25 ABHIYAAN RALLY ON 16. SANVIDHAN NSS UNIT 13/01/2020 AKOLNER VILLAGE 25 JAGRUTI ABHIYAN FREE MEDICAL CHECKUP ON KRSNAA 17. OSTEOPOROSIS & DIAGNOSTICS & 14/01/2020 AKOLNER VILLAGE 25 ORAL MOUTH NSS UNIT CANCER LECTURE ON DR. NIVEDITA 18. HEALTH MANE [ ZP 14/01/2020 AKOLNER VILLAGE 25 AWARENESS AROGYA VIBHAG ] WORLD CANCER MAXIMUS : DAY : NAGAR 19. NAGAR RISING 02/02/2020 A.NAGAR CITY 32 RISING HALF HALF MARATHON MARATHON DISTRIBUTION OF MASK, SANITIZER, GROCERRY TO MAHAPALIKA BEED, A.NAGAR 20. NSS UNIT APRIL 2020 03 SWACHHATA CITY KARMACHARI , NEEDY & POOR CLASS PEOPLES COMMUNITY OUT REACH ACTIVITY REPORTS (2018-2019) NAME OF NO. OF SR. SPEAKER / DATE OF PLACE OF THE STUDENTS / NAME OF ACTIVITY NO. ORGANISATION ACTIVITY ACTIVITY STAFF IF ANY PARTICIPATED 1. DONATED ROBINHOOD GROCERRY TO 15/08/2018 A.NAGAR CITY 150 ARMY ROBINHOOD ARMY C.B.C. & THYROID CIVIL HOSPITAL JAKHANGAON ESTIMATION OF 2. ( MAHAHIND VILLAGE ( NSS 25 VILLAGERS & ZP 09/01/2019 LABS) &NSS Unit SPECIAL CAMP ) SCHOOL STUDENTS LECTURE ON JAKHANGAON VITTIYA 3. DR. M.P. SHARMA 09/01/2019 VILLAGE(NSS 25 SAKSHARATA SPECIAL CAMP) ABHIYAN JAKHANGAON RALLY ON CANCER 4. VILLAGE(NSS 25 AWARENESS N.S.S. Unit 09/01/2019 SPECIAL CAMP) ENERGY AUDIT OF JAKHANGAON 5. 25 VILLAGE N.S.S. Unit 10/01/2019 VILLAGE(NSS SPECIAL CAMP) AVAYAV DAAN & DR. S.M. AHIRE JAKHANGAON 6. NETRA DAAN (Civil Hospital ) & 10/01/2019 VILLAGE(NSS 25 ABHIYAN NSS Unit SPECIAL CAMP) COMPUTER JAKHANGAON 7. TEACHING TO ZP N.S.S. Unit 11/01/2019 VILLAGE (NSS 25 SCHOOL STUDENTS SPECIAL CAMP) JAKHANGAON TREE PLANTATION 8. N.S.S. Unit 11/01/2019 VILLAGE(NSS 25 ACTIVITY SPECIAL CAMP) LECTURE ON JAKHANGAON 9. PERSONALITY DR. R.K. PARDESI 11/01/2019 VILLAGE(NSS 25 DEVELOPMENT SPECIAL CAMP) DR. MRS. JADHAV JAKHANGAON LECTURE ON YOGA 10. M.L.(Civil Hospital 12/01/2019 VILLAGE(NSS 25 & MANASOPCHAR )&NSS Unit SPECIAL CAMP) JAKHANGAON BETI BACHAO BETI 11. N.S.S. Unit 12/01/2019 VILLAGE(NSS 25 PADHAO ABHIYAN SPECIAL CAMP) LECTURE ON DR. SUNIL JAKHANGAON HEALTH 12. GANDHE&NSS 13/01/2019 VILLAGE(NSS 25 AWARENESS Unit SPECIAL CAMP) PROGRAM WORLD CANCER MAXIMUS : 13. DAY : NAGAR RISING NAGAR RISING 03/02/2019 A.NAGAR CITY 32 HALF MARATHON HALF MARATHON COMMUNITY OUT REACH ACTIVITY REPORTS (2017-2018) NO. OF PLACE OF NAME OF SPEAKER / STUDENTS / SR. NO. NAME OF ACTIVITY DATE OF ACTIVITY THE ORGANISATION IF ANY STAFF ACTIVITY PARTICIPATED C.B.C. & OSTEOPOROSIS CIVIL HOSPITAL , ESTIMATION OF 1. KRSNNA DIAGNOSTICS NIMBALAK 25 VILLAGERS &ZP SCHOOL 08/01/2018 &NSS UNIT VILLAGE STUDENTS MR. S.M. AHIRE [ DIST. COORDINATOR – RALLY & LECTURE ON CIVIL HOSPITAL ORGAN 2. AVAYAV DAAN & 09/01/2018 NIMBALAK 25 DONATION NETRA DAAN ABHIYAN VILLAGE DEPARTMENT ]& NSS UNIT COMPUTER TEACHING NIMBALAK 3. TO ZP SCHOOL NSS UNIT 09/01/2018 25 VILLAGE STUDENT DR. MRS. DONGARE CANCER AWARENESS [CIVIL HOSPITAL 10/01/2018 NIMBALAK 25 4. RALLY & LECTURE CANCER DEPARTMENT] VILLAGE GRAM SWACHHATA NIMBALAK 5. NSS UNIT 10/01/2018 25 ABHIYAN VILLAGE MR. SACHIN BHAGAT & LECTURE ON VITTIYA MR. JADHAV RAJENDRA NIMBALAK 6. 11/01/2018 25 SAKSHRATA ABHIYAAN [ Pay tm – TERRITORY VILLAGE MANAGER] HELPING HANDS BY PROVIDING GROCERRY & CLOTHES TO SHINGAVE 7. NSS UNIT 12/01/2018 25 MENTALLY RETARDED NAIK PEOPLES AT MAULI SEVA SANSTHA LECTURE ON SOCIAL AWARENESS & PROF. MR. GIRISH 8. 12/01/2018 NIMBALAK 25 PERSONALITY KUKREJA VILLAGE DEVELOPMENT RALLY ON BETI BACHAO NIMBALAK 9. N.S.S. UNIT 13/01/2018 25 BETI PADHAO ABHIYAN VILLAGE LECTURE ON YOGA & DR. MRS. JADHAV M.L.[ NIMBALAK 10. 13/01/2018 25 MANASOPCHAR CIVIL HOSPITAL] VILLAGE TREE PLANTATION AT NIMBALAK 11. NSS UNIT 13/01/2018 25 NIMBALAK VILLAGE WORLD CANCER DAY : MAXIMUS : NAGAR A.NAGAR 12. NAGAR RISING HALF RISING HALF 04/02/2018 32 CITY MARATHON MARATHON RADHABAI WORLD WOMAN’S DAY KALE YOUTH INSPIRATOR’S 13. : POWADA ON WOMAN 08/03/2018 MAHILA 25 NETWORK [ YIN ] EMPOWERMENT MAHAVIDYA LAYA WORLD BLOOD CIVIL DONATION DAY : CIVIL HOSPITAL, 14. 14/06/2018 HOSPITAL,A. 01 POSTER PRESENTATION A.NAGAR NAGAR COMPETITION COMMUNITY OUT REACH ACTIVITY REPORTS (2016-2017) NO. OF NAME OF SPEAKER / SR. DATE OF PLACE OF THE STUDENTS / NAME OF ACTIVITY ORGANISATION IF NO. ACTIVITY ACTIVITY STAFF ANY PARTICIPATED DONATED B.S.D. UNIT OF GROCERRY TO DR.V.V.P.F’S, COLLEGE SNEHALAYA 27/10/2016 10 1. SNEHALAYA OF PHARMACY,VILAD SANSTHA SANSTHA GHAT , A.NAGAR COMPUTER NIMBALAK 2. TEACHING TO ZP NSS UNIT 16/01/2017 25 VILLAGE SCHOOL STUDENTS NSS UNIT & DR.K.N. RALLY & LECTURE DHAMANE , DR. GIRI NIMBALAK ON AIDS 17/01/2017 25 3. SUNIL [ CIVIL VILLAGE AWARENESS HOSPITAL ] GRAM SWACHHATA NIMBALAK 4. NSS UNIT 18/01/2017 25 ABHIYAAN VILLAGE ROAD PATCHING & 5. MAINTENANCE AT NSS UNIT 18/01/2017 NIMBALAK 25 NIMBALAK VILLAGE LECTURE ON MR. NILESH CHAVAN VITTIYA 6. [ Paytm – Territory 18/01/2017 NIMBALAK 25 SAKSHARATA Manager ] & NSS UNIT VILLAGE ABHIYAAN MR. S.M. AHIRE RALLY & LECTURE [ DIST.COORDINATOR : ON AVAYAV DAAN ORGAN DONATION 7. 19/01/2017 NIMBALAK 25 & NETRA DAAN DEPARTMENT CIVIL VILLAGE ABHIYAN HOSPITAL ] & NSS UNIT LECTURE ON BETI PROF. MR. NIMBALAK 8. BACHAO BETI MAKARAND KHER & 20/01/2017 25 VILLAGE PADHAO ABHIYAN NSS UNIT LECTURE ON MRS. U.B. BAWAKE SWACHHATA [ ZP AROGYA VIBHAG] 20/01/2017 NIMBALAK 25 9. ABHIYAAN & NSS UNIT VILLAGE DR. MRS. JADHAV LECTURE ON YOGA NIMBALAK 10. M.L.[CIVIL HOSPITAL] 21/01/2017 25 & MANASOPCHAR VILLAGE & NSS UNIT TREE PLANTATION NIMBALAK 11. AT DHARAMPURI, NSS UNIT 21/01/2017 25 VILLAGE NIMBALAK WORLD CANCER MAXIMUS : NAGAR DAY : NAGAR 12. RISING HALF 04/02/2017 A.NAGAR CITY 32 RISING HALF MARATHON MARATHON COMMUNITY OUT REACH ACTIVITY REPORTS (2015-2016) NO. OF NAME OF SPEAKER / SR. DATE OF PLACE OF THE STUDENTS / NAME OF ACTIVITY ORGANISATION IF NO. ACTIVITY ACTIVITY STAFF ANY PARTICIPATED FOOD & DRUG ANTITOBACCO ADMINISTRATION 1. CAMPAIGNACTIVITY [FDA]& DR.V.V.P.F’S, 29/01/2016 A.NAGAR CITY 32 : BIKE RALLY COLLEGE OF PHARMACY, A.NAGAR DR.V.V.P.F’S, COLLEGE OF WORLD CANCER PHARMACY & FOOD A.NAGAR CITY 2. DAY : CANCER 04/02/2016 120 & DRUG AWARENESS RALLY ADMINISTRATION [FDA] , A.NAGAR PLACEMENT DATA FOR YEAR 2015 – 2016 (PG) Name of the Students Date of Interview / Placed SR. No Stream Name of the Organization. Salary Appointed. Joining. Through Raptim Research Ltd. : A-226 / A-242, TTC Industrial Area, Mahape MIDC, 28 / 07 / 2015 01. Shinde Abhishek K. P’Chem. T &P Cell 1,44,000 NaviMumbai-400701 Phone : +91-22-2778 1887/1889 Centaur Pharmaceuticals Ltd.: CENTAUR HOUSE Opp. Grand Hyatt, Vakola, Santacruz - East, Mumbai - 400 055, India. Tel.: +91 (022) 6649 20 / 08 / 2015 02. Pawa Karan P’Chem. 9100 Fax: +91 (022) 6649 9108 / 112 T &P Cell 1,80,000 Email: [email protected], Website: www.centaurpharma.com Saket Surgicals ltd. , Supa MIDC, Taluka – Parner, 03. Rupnar Kiran Q.A.T. July 2015 T &P Cell 1,80,000 Dist.-A.Nagar Nav Maharashtra Shikshan Mandal’s, Abasaheb Kakade College of Pharmacy : A/P BodhegaonTal 04. Thanage Somnath P’Cology. Shevgaon, Ahmednagar, Maharashtra 414502 , July 2015 T &P Cell 1,80,000 Phone : 02429 240 295 , e-mail id : [email protected] Nav Maharashtra Shikshan Mandal’s, Abasaheb Kakade College of Pharmacy : A/P BodhegaonTal 05.
Recommended publications

  • Sr. No. College Name University Name Taluka District JD Region

    Non-Aided College List Sr. College Name University Name Taluka District JD Region Correspondence College No. Address Type 1 Shri. KGM Newaskar Sarvajanik Savitribai Phule Ahmednag Ahmednag Pune Pandit neheru Hindi Non-Aided Trust's K.G. College of Arts & Pune University, ar ar vidalaya campus,Near Commerece, Ahmednagar Pune LIC office,Kings Road Ahmednagrcampus,Near LIC office,Kings 2 Masumiya College of Education Savitribai Phule Ahmednag Ahmednag Pune wable Non-Aided Pune University, ar ar colony,Mukundnagar,Ah Pune mednagar.414001 3 Janata Arts & Science Collge Savitribai Phule Ahmednag Ahmednag Pune A/P:- Ruichhattishi ,Tal:- Non-Aided Pune University, ar ar Nagar, Dist;- Pune Ahmednagarpin;-414002 4 Gramin Vikas Shikshan Sanstha,Sant Savitribai Phule Ahmednag Ahmednag Pune At Post Akolner Tal Non-Aided Dasganu Arts, Commerce and Science Pune University, ar ar Nagar Dist Ahmednagar College,Akolenagar, Ahmednagar Pune 414005 5 Dr.N.J.Paulbudhe Arts, Commerce & Savitribai Phule Ahmednag Ahmednag Pune shaneshwar nagarvasant Non-Aided Science Women`s College, Pune University, ar ar tekadi savedi Ahmednagar Pune 6 Xavier Institute of Natural Resource Savitribai Phule Ahmednag Ahmednag Pune Behind Market Yard, Non-Aided Management, Ahmednagar Pune University, ar ar Social Centre, Pune Ahmednagar. 7 Shivajirao Kardile Arts, Commerce & Savitribai Phule Ahmednag Ahmednag Pune Jambjamb Non-Aided Science College, Jamb Kaudagav, Pune University, ar ar Ahmednagar-414002 Pune 8 A.J.M.V.P.S., Institute Of Hotel Savitribai Phule Ahmednag Ahmednag
  • SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI Trading As ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP

    SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI Trading As ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP

    Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI trading as ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP. COTTON GREEN RLY. STN. MUMBAI-400033. MANUFACTURE & MERCHANT INDIAN NATIONAL Used Since :31/01/2001 MUMBAI MEDICINAL PREPARATIONS. 537 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SEPTIGARD 1741718 08/10/2008 INDERJIT SINGH trading as ;INDERJIT SINGH B-104 , SWASTHYA SINGH , NEW DELHI -92 MERCHANTS & MANUFACTUERERS Address for service in India/Agents address: MAHTTA & CO. 43 - B/3, MAHTTA HOUSE,UDHAM SINGH NAGAR, LUDHIANA - 141 001, (PUNJAB). Proposed to be Used DELHI MEDICINAL & PHARMACEUTICAL PREPARATIONS. 538 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 FAIR & BEAUTY 1803779 08/04/2009 GALPHA LABORATORIES LIMITED 221, Kanakia Zillion, E Wing Bandra Kurla Complex Annex LBS Marg & CST Road Junction Kurla West MUMBAI 400070 MANUFACTURERS AND MERCHANTS INDIAN NATIONAL Used Since :15/11/2007 MUMBAI PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES 539 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 O-BAMA 1815900 08/05/2009 KREMOINT PHARMA PVT. LTD. 151/5, SHRI KRISHNA DARSHAN, GARODIA NAGAR, GHATKOPAR (E), BOMBAY-400 077. MANUFACTURERS AND MERCHANTS. A CORPORATE ENTITY INCORPORATED IN INDIA UNDER THE COMPANIES ACT 1956. Address for service in India/Attorney address: KRISLAW CONSULTANTS BUILDING NO.4, C/104, SHANKESHWAR PALMS, BEHIND MODEL SCHOOL, KUMBHARKHANPADA, SUBHASH ROAD, DOMBIVILI(W) 421202 Used Since :02/05/2009 MUMBAI PHARMACETICAL AND MEDICINAL PREPARATIONS. 540 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 AYUSHAKTI D-VYRO 1815928 08/05/2009 SMITA NARAM BUNGALOW NO.31, NEXT TO M.
  • 50 KW Offer Solar Copy 2

    50 KW Offer Solar Copy 2

    21st Century Enviro Engineers Pvt.Ltd. Plot No. 120(10 Marla), COMPANY Industrial Area Phase II Chandigarh - 160002, India PROFILE www.21stcenturyenviro.com INTRODUCTION 21st CENTURY ENVIRO ENGINEERS PVT. LTD. is a Company dealing in the field of Environmental Engineering related activities. We are Registered Environmental Consultants of Pollution Control Board to Supply ETP’s, STP’s, APCD’s, Incinerators, Water Treatment Plants, Reverse Osmosis, Evaporators, Solid Waste Management and Rain Water Harvesting and to carry out EIA Studies . The Directors of the company are young Technocrats having versatile experience in this field. We have a back up of highly qualified and experienced technical team having versatile experience in Designing, Erection, Commissioning and Operation of different types of Effluent Treatment Plants. Our Managing Director himself is a Chemical Engineer with almost 25 Years Experience in this line and Technical Director is PhD. in Environmental Science with almost 30 Years working experience on various types of effluent treatment Technologies. Our team comprises of almost 150 people from different backgrounds e.g. Chemical, Environmental, Mechanical, Instrumentation, Civil, Accounts, Purchase, Marketing etc. We have our Marketing/ Design Office in Chandigarh and regional offices in Dhaka, Mumbai, New Delhi, Sikkim etc. and have our own testing Laboratory for Effluent/Water Testing and to study treatability of effluent on pilot scale. We have our own full-fledged manufacturing unit of Pollution Control Equipments in Village Kunjhal Baddi (HP). We also undertake annual operation and maintenance contracts and liasining services for the systems supplied by us. We are also Registered with CREST (Chandigarh Renewable Energy & Technology Promotion Society) and SECI (Solar Energy Corporation of India) for supplying Online/Offline Solar systems in Chandigarh, Himachal Pradesh, Uttarakhand, J&K, Punjab, Haryana, Delhi, Bihar etc.
  • Glenmark Pharmaceuticals (GLEPHA)

    Glenmark Pharmaceuticals (GLEPHA)

    Glenmark Pharmaceuticals (GLEPHA) CMP: | 483 Target: | 560 (16%) Target Period: 12 months BUY August 17, 2020 Subdued topline; margin expansion to the fore… Revenues stayed flattish growing just 0.9% YoY to | 2345 crore due to subdued growth of 1.6% in US to | 743 crore, 3.7% growth in domestic sales to | 780 crore. Europe business grew 12.8% YoY to | 274 crore. RoW markets de-grew 18.1% YoY to 212 crore. EBITDA margins improved 567 bps YoY to 20.4% mainly due to lower other expenditure. EBITDA grew Particulars 39.8% YoY to | 478 crore. Adjusted PAT grew 106.9% YoY to | 226 crore. P articular Am ount Delta vis-à-vis EBITDA was due to higher other income. Exceptional items in Market Capitalisation | 13615 crore Q1FY21 were | 28 crore on gain arising from sale of Vwash brand to HUL. Debt (FY20) | 4868 crore Result Update Result Cash & equivalent (FY20) | 1111 crore US growth dependent on new launches E V | 17371 crore 52 week H/L (|) 573/168 US generics comprise ~30% of total revenues. So far, the company has E quity capital | 28.2 crore Face value | 1 received approval for 164 ANDAs while another 44 are pending approval, of which 24 are Para IV applications. However, Glenmark’s derma portfolio is Key Highlights facing stiff pricing pressure in the US. Going ahead, traction from the newly commissioned US based Monroe facility will be the key determinant besides Q1FY21 revenues remained flattish sustained product launches. We expect the US to grow at 5.2% CAGR in due to subdued US growth amid FY20-22E to | 3479 crore on the back of new launches.
  • Hy Sun Missed the Pharma Rally: the Answer Is Hidden in a Bet Many Failed — Speciality Drugs - the Economic Times

    Hy Sun Missed the Pharma Rally: the Answer Is Hidden in a Bet Many Failed — Speciality Drugs - the Economic Times

    12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets News Industry RISE Politics Wealth MF Tech Jobs Opinion NRI Panache ET NOW More Aayush English Edition | E-Paper Tech Consumer Markets Corporate Governance Telecom + OTT Auto + Aviation Pharma Fintech + BFSI Economy Infra Environment Energy Business News › Prime › Pharma › Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Getty Images MARKETS hy Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Dilip Shanghvi, founder and managing director, Sun Pharmaceuticals Synopsis Sun Pharma is the only Indian company to have made some inroads into speciality drugs. What worries investors is high investments and uncertainties over ramp up in revenue. The stock can still see upside because of its current valuations, strong India business, and any positive surprises in US generic business. But it is crucial that its speciality bet pays off. BACK TO TOP https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-sun-missed-the-pharma-rally-the-answer-is-hidden-in-a-bet-many-failed-spe… 1/11 12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets NeCwasllI nitd uas trbyleRssISiEngP oilniti cdsisWgeuailthse fMoFr tTheceh InJodbisanOpinion NRI Panache ET NOW More pharmaceutical industry. The stocks of pharma companies have been on a tear since the beginning of the Covid-19 crisis.
  • DIA India ICH Day 2019 Enhancing Clinical Trial Outcomes with ICH 30Th August, 2019 | Taj Lands End | Mumbai, India

    DIA India ICH Day 2019 Enhancing Clinical Trial Outcomes with ICH 30Th August, 2019 | Taj Lands End | Mumbai, India

    DIA India ICH Day 2019 Enhancing Clinical Trial Outcomes with ICH 30th August, 2019 | Taj Lands End | Mumbai, India PROGRAMME COMMITTEE Today, the Indian pharmaceutical industry supplies approximately 20% of the world’s generic drugs and has the largest number of FDA-approved manufacturing facilities C. Michelle Limoli outside of the US. This industry has evolved during the past decade into innovative drug Senior International development, including new chemical and biological entities, biosimilars, and innovative Health Science Advisor differentiated products. At the same time, as healthcare costs continue to rise across the US FDA world, so does the global need for affordable, innovative healthcare. Against this backdrop, DIA India aims to create an initiative that will address the clinical and regulatory aspects Ramesh Jagannathan of drug development, through a comprehensive single day workshop on the latest ICH Associate Vice President guidelines and developments relevant for India. - R&D Biocon Ltd. Objective Anupama Ramkumar CEO and Principal The objective of this program is to provide a common platform for ICH trainers, regulatory Consultant authorities, academia, investigators, service providers, and the Indian biopharmaceutical Arkus Research Pvt. Ltd. industry, to deliberate upon and understand ICH guidelines and the most recent updates, impacting the drug development spectrum including key clinical, regulatory and quality Seema Pai aspects. Director - India Cluster Global Site & Study Take a look at our key topics for the event

  • Ajanta Pharma Limited

    AJANTA PHARMA LIMITED CIN : L24230MH1979PLC022059 Registered & Corporate Office: ‘Ajanta House’, 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India Tel.: +91 22 6606 1000, Fax: +91 22 6606 1200 | E-mail: [email protected] | Website: www.ajantapharma.com POST BUYBACK PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF EQUITY SHARES OF AJANTA PHARMA LIMITED This public announcement (the “Post Buyback Public Announcement”) is being made pursuant to the provisions of Regulation 24(vi) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, for the time being in force including any statutory modifications and amendments from time to time (the “Buyback Regulations”). This Post Buyback Public Announcement should be read in conjunction with the Public Announcement dated November 4, 2020 which was published on November 5, 2020 (the “Public Announcement”) and the letter of offer dated November 25, 2020 (the “Letter of Offer”) issued in connection with the Buyback. The terms used but not defined in this Post Buyback Public Announcement shall have the same meanings as assigned in the Public Announcement and the Letter of Offer. 1. THE BUYBACK 1.1 Ajanta Pharma Limited (the “Company”) had announced the Buyback of not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) fully paid-up equity shares of face value of ₹2 each (“Equity Shares”) from all the existing shareholders / beneficial owners of Equity Shares as on the record date (i.e. Friday, November 13, 2020), on a proportionate basis, through the “Tender Offer” process at a price of ₹1,850/- (Rupees One Thousand Eight Hundred and Fifty Only) per Equity Share payable in cash for an aggregate consideration not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding the Transaction Costs (“Buyback Offer Size”).
  • Inner 25 India Pharma & Healthcare Fund

    Inner 25 India Pharma & Healthcare Fund

    Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata India Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th June 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 55184.24 97.88 Glenmark Pharmaceuticals Ltd. 167000 1089.76 1.93 INVESTMENT OBJECTIVE Healthcare Services Sanofi India Ltd. 13000 997.39 1.77 The investment objective of the scheme is to seek long Apollo Hospitals Enterprise Ltd. 70500 2551.99 4.53 Gland Pharma Ltd. 19662 673.29 1.19 term capital appreciation by investing atleast 80% of its Fortis Healthcare Ltd. 795000 1935.03 3.43 Laurus Labs Ltd. 90000 619.79 1.10 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Syngene International Ltd. 265000 1545.75 2.74 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Narayana Hrudayalaya Ltd. 301420 1483.74 2.63 Other Equities^ 1186.14 2.10 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd.
  • MF 35 Fund One Pager

    MF 35 Fund One Pager

    BR“BuyS RightT : BSit TightR” ST BRSnowT Bin fourRS differentTBRS colorsTBRS BRSTBRSTBRSTBR Motilal Oswal MOSt Focused Invests in enduring B25 RFund STBRSTBwRealth creaStors T Motilal Oswal MOSt Focused Invests in emerging BMidcapR 30 Fund TBRwealth creators T BRSTBSRSTBRSTBSRS Motilal Oswal MOSt Focused Invests in emerging and BMulticapRS 35 FundT BRSTBRenduringST wealthB creatorRs Lock in fund that invests Motilal Oswal MOSt Focused in wealth creators BLongR Term SFund TBRSTBplusR Saves TSax T BR TBR T BRSTBSRSTBRSTBSRS Focused Low Churn QGLP No load BRSTBPortfolioRSTBPortfolioRSTStocksBR BRSInvesTt nowB to addR colorSs Tto yourB porRolioST BRSCall:T 1800-200-6626B | SMS:R FOCUSS to 575753T BRSTBRS Website: www.motilaloswalmf.com Our Investment Philosophy The recommended way to create Wealth from equity- 'Buy Right : Sit Tight' At Molal Oswal Asset Management Company (MOAMC), our investment philosophy and invesng style is centered on 'Buy Right: Sit Tight‘ principal. ‘Buy Right' means buying quality companies at a reasonable price and 'Sit Tight' means staying invested in them for a longer me to realise the full growth potenal of the stocks. Buy Right Stock Characteristics Sit Tight Approach QGLP ‘Q’uality denotes quality of the business and Buy and Hold: We are strictly buy and hold management investors and believe that picking the right ‘G’rowth denotes growth in earnings and business needs skill and holding onto these sustained RoE businesses to enable our investors to benefit from the entire growth cycle needs even more ‘L’ongevity denotes longevity of the skill. competitive advantage or economic moat of the business Focus: Our portfolios are high conviction portfolios with 20 to 25 stocks being our ideal ‘P’rice denotes our approach of buying a good n u m b e r.
  • CARE Ratings Ltd

    CARE Ratings Ltd

    CARE/HO/RL/2020-21/2749 Mr. Arvind Agrawal Chief Financial Officer Ajanta Pharma Limited Ajanta House, Charkop, Kandivali (W), Mumbai-400067 October 1, 2020 Confidential Dear Sir, Credit rating for bank facilities On the basis of recent developments including operational and financial performance of your company for FY20 (audited) and Q1FY21 (provisional), our Rating Committee has reviewed the following ratings: Facilities Amount Rating1 Rating (Rs. crore) Action Long-term/Short-term Bank 55.00 CARE AA; Stable/CARE A1+ Facilities (reduced from 87.50) (Double A; Outlook: Stable/A Reaffirmed One Plus) Total 55.00 (Rs. Fifty Five crore only) 2. Refer Annexure 1 for details of rated facilities. 3. The rationale for the rating will be communicated to you separately. A write-up (press release) on the above rating is proposed to be issued to the press shortly, a draft of which is enclosed for your perusal as Annexure-2. We request you to peruse the annexed document and offer your comments if any. We are doing this as a matter of courtesy to our clients and with a view to ensure that no factual inaccuracies have inadvertently crept in. Kindly revert as early as possible. In any case, if we do not hear from you by October 5, 2020 we will proceed on the basis that you have no any comments to offer. 4. CARE reserves the right to undertake a surveillance/review of the rating from time to time, based on circumstances warranting such review, subject to at least one such review/surveillance every year. 5.
  • Company Reliance Industries Limited Tata Consultancy Services

    Company Reliance Industries Limited Tata Consultancy Services

    Top 1000 Private Sector Companies (Rank-wise List) Company Reliance Industries Limited Tata Consultancy Services (TCS) Infosys Technologies Ltd Wipro Limited Bharti Tele-Ventures Limited ITC Limited Hindustan Lever Limited ICICI Bank Limited Housing Development Finance Corp. Ltd. TATA Steel Limited Ranbaxy Laboratories Limited HDFC Bank Ltd Tata Motors Limited Larsen & Toubro Limited (L&T) Satyam Computer Services Ltd. Maruti Udyog Limited Bajaj Auto Ltd. HCL Technologies Ltd. Hero Honda Motors Limited Hindalco Industries Ltd Reliance Energy Limited Grasim Industries Limited Jet Airways (India) Ltd. Sun Pharmaceuticals Industries Ltd Cipla Ltd. Gujarat Ambuja Cements Ltd. Videsh Sanchar Nigam Limited The Tata Power Company Limited Sterlite Industries (India) Ltd. Associated Cement Companies Ltd. Nestlé India Ltd. Hindustan Zinc Limited GlaxoSmithKline Pharmaceuticals Limited Siemens India Ltd. Motor Industries Company Limited Mahindra & Mahindra Limited UTI Bank Ltd. Zee Telefilms Limited Bharat Forge Limited ABB Limited i-Flex Solutions Ltd. Dr. Reddy's Laboratories Ltd. Nicholas Piramal India Limited Kotak Mahindra Bank Limited Reliance Capital Ltd. Ultra Tech Cement Ltd. Patni Computer Systems Ltd. Wockhardt Limited Indian Petrochemicals Corporation Limited Biocon India Limited Essar Oil Limited. Asian Paints Ltd. Dabur India Limited Jaiprakash Associates Limited JSW Steel Limited Tata Chemicals Limited Tata Tea Limited Tata Teleservices (Maharashtra) Limited The Indian Hotels Co. Ltd. Glenmark Pharmaceuticals Limited NIRMA Limited Jindal Steel & Power Ltd HCL Infosystems Ltd. Cadila Healthcare Limited Colgate-Palmolive (India) Limited The Great Eastern Shipping Company Limited Aventis Pharma India Ltd Ashok Leyland Limited Pantaloon Retail (India) Limited Indian Rayon And Industries Limited Financial Technologies (India) Ltd United Phosphorus Limited Matrix Laboratories Limited Sesa Goa Limited Lupin Ltd Cummins India Limited Crompton Greaves Limited.
  • Final Placement Report 2020-21

    Final Placement Report 2020-21

    FINAL PLACEMENT REPORT POST GRADUATE ProgrAM IN MANAGEMENT (PGP) 2019-21 12th BAtcH INDIAN INSTITUTE OF MANAGEMENT SHILLONG FOREWORD The Placement Committee of IIM Shillong takes immense pride in announcing the successful completion of the final placement season for the PGP batch of 2019-21. The stellar performance by the PGP participants stands testimony to the rapid progress made by IIM Shillong and has once again established IIM Shillong as the preferred choice for recruiters. We express our gratitude to our regular recruiters who have continuously believed in the mettle of our students and have furthered their association with us for another year to facilitate this mutually beneficial relationship. We are also grateful to our new recruiters, who have acknowledged the potential of our students and provided them with a plethora of opportunities. We appreciate the contribution of the entire IIM Shillong fraternity for their sustained assistance in the placement process. With continued support from students, recruiters, faculty, alumni, staff and management, we hope to carry this momentum onto the next academic year. Prof. Rohit Joshi Chairperson Placement Committee IIM Shillong BATCH PROFILE OF 2019-21 Education Background 9% 9% 9% 57% 198 16% Number 61% 39% of Students Male Female Engineering Arts Commerce & Finance Others Science Work Experience by Months Domain wise Work Experience Freshers 27% Information Technology & Analytics 47% 01-12 months 23% Consulting & Strategy 13% 19% Finance 23% 13-24 months 18% Sales & Marketing 11% 25-36